Literature DB >> 32654681

Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.

Mark S Freedman1, Virginia Devonshire2, Pierre Duquette3, Paul S Giacomini4, Fabrizio Giuliani5, Michael C Levin6, Xavier Montalban7, Sarah A Morrow8, Jiwon Oh7, Dalia Rotstein7, E Ann Yeh9.   

Abstract

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization recommendations (TORs) on the optimal use of disease-modifying therapies for patients with all forms of multiple sclerosis (MS). Recommendations provide guidance on initiating effective treatment early in the course of disease, monitoring response to therapy, and modifying or switching therapies to optimize disease control. The current TORs also address the treatment of pediatric MS, progressive MS and the identification and treatment of aggressive forms of the disease. Newer therapies offer improved efficacy, but also have potential safety concerns that must be adequately balanced, notably when treatment sequencing is considered. There are added discussions regarding the management of pregnancy, the future potential of biomarkers and consideration as to when it may be prudent to stop therapy. These TORs are meant to be used and interpreted by all neurologists with a special interest in the management of MS.

Entities:  

Keywords:  MULTIPLE SCLEROSIS; Recommendations; Sequencing; THERAPEUTICS; Treatment optimization

Mesh:

Substances:

Year:  2020        PMID: 32654681     DOI: 10.1017/cjn.2020.66

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  10 in total

Review 1.  Emerging therapies to target CNS pathophysiology in multiple sclerosis.

Authors:  Jiwon Oh; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2022-06-13       Impact factor: 44.711

Review 2.  Therapeutic Advances in Multiple Sclerosis.

Authors:  Jennifer H Yang; Torge Rempe; Natalie Whitmire; Anastasie Dunn-Pirio; Jennifer S Graves
Journal:  Front Neurol       Date:  2022-06-03       Impact factor: 4.086

3.  Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.

Authors:  Patrick Vermersch; Celia Oreja-Guevara; Aksel Siva; Bart Van Wijmeersch; Heinz Wiendl; Jens Wuerfel; Regine Buffels; Karen Kadner; Thomas Kuenzel; Giancarlo Comi
Journal:  Eur J Neurol       Date:  2021-11-25       Impact factor: 6.288

Review 4.  Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation.

Authors:  Simon Thebault; Ronald A Booth; Carolina A Rush; Heather MacLean; Mark S Freedman
Journal:  Front Neurosci       Date:  2021-03-25       Impact factor: 4.677

Review 5.  The need for a strategic therapeutic approach: multiple sclerosis in check.

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  Ther Adv Chronic Dis       Date:  2022-01-18       Impact factor: 5.091

6.  Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β.

Authors:  Úrsula Muñoz; Cristina Sebal; Esther Escudero; Elena Urcelay; Rafael Arroyo; Maria A García-Martínez; Francisco J Quintana; Roberto Álvarez-Lafuente; Maria Cruz Sádaba
Journal:  Sci Rep       Date:  2022-08-03       Impact factor: 4.996

7.  Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.

Authors:  Corey C Ford; Jeffrey A Cohen; Andrew D Goodman; John W Lindsey; Robert P Lisak; Christopher Luzzio; Amy Pruitt; John Rose; Horea Rus; Jerry S Wolinsky; Shaul E Kadosh; Emily Bernstein-Hanlon; Yafit Stark; Jessica K Alexander
Journal:  Mult Scler       Date:  2022-06-29       Impact factor: 5.855

8.  The road to conception for women with multiple sclerosis.

Authors:  Dessa Sadovnick; Maria Criscuoli; Irene Yee; Robert Carruthers; Alice Schabas; Penelope Smyth
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-07-15

9.  Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.

Authors:  Samuel Lees; Mathew Dicker; Jie En Ku; Varun Chaganti; Matthew Mew-Sum; Nick Wang; Angela Smith; Christopher Oldmeadow; Wooi Lynn Goon; Marc Bevan; Danielle Lang; Madeleine Hinwood
Journal:  BMJ Open       Date:  2021-11-02       Impact factor: 2.692

10.  Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.

Authors:  Bianca Weinstock-Guttman; Robert Bermel; Gary Cutter; Mark S Freedman; Thomas P Leist; Xiaoye Ma; Deidre Kile; Bruno Musch; Anthony T Reder; Jerry S Wolinsky
Journal:  Mult Scler       Date:  2021-08-12       Impact factor: 6.312

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.